Deere & Co. Stock Falls As Tariffs Impact Earnings
The stock of Deere & Co. (DE) is down 7% after the maker of John Deere tractors and lawnmowers lowered its guidance due to tariff impacts.The company known for its distinctive green and yellow farm equipment reported earnings per share (EPS) of $4.75 U.S. on sales of $10.4 billion U.S. The results were better than Wall Street forecast of $4.58 U.S. in earnings and revenue of $10.3 billion U.S. Despite the top- and bottom-line beats, Deere’s agricultural and construction equipment business saw sales decline for a third consecutive quarter, marking a slowdown at the company. Deere’s guidance also disappointed. Management said they expect net income guidance for the entire fiscal year of $5 billion U.S., down from $5.25 billion U.S. previously and below analysts’ consensus expectation. Deere executives also said that tariffs increased product costs in the latest quarter, though they didn’t say by how much.Equipment purchases from Deere & Co. are falling as farmers’ incomes decline due to depressed crop prices. The price of corn averaged roughly $6.50 U.S. a bushel in 2022 compared with $4 U.S. over the last 12 months.Deere said it needs to overcome high inventory levels with dealers. The company says it has been working to reduce new and used inventory at dealers for months. Prior to today (Aug. 14), DE stock had risen 23% this year to trade at $513.54 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


